Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Study designs and tests 60 compounds for their ability to kill human cancer cells

Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.

28 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

C-section babies more likely to develop allergies

For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two.

25 Feb 2013

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

Race and possibly genetics play a role in children's sensitivity to developing allergies

Research conducted at Henry Ford Hospital shows that race and possibly genetics play a role in children's sensitivity to developing allergies.

24 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

Antibody delivery system launched that works even in presence of additives

...

22 Feb 2013

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Napoleone Ferrara, MD, PhD, the molecular biologist credited with helping decipher how tumors grow and now senior deputy director for basic sciences at the University of California, San Diego Moores Cancer Center, was today named one of 11 recipients of the inaugural Breakthrough Prize in Life Sciences, which comes with a $3 million cash award.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Possible alternative to biopsy discovered for renal cancer diagnosis

Combining positron emission tomography scanning with iodine-124 (124I)–girentuximab may offer an effective noninvasive method of diagnosing clear cell renal cell carcinoma in patients who present with a renal mass, US study results suggest.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Among healthy adults who were administered a cold virus, those with shorter telomere length (a structure at the end of a chromosome) in certain cells were more likely to develop experimentally-induced upper respiratory infection than participants with longer telomeres, according to results of preliminary research published in the February 20 issue of JAMA.

20 Feb 2013

Antibody test ‘inappropriate’ without connective tissue symptoms

The positive antinuclear antibody test is often used inappropriately in patients without indications of connective tissue disease, real-world research suggests.

18 Feb 2013

Researchers explore cellular signals produced by the body in response to traumatic injury

When it comes to healing the terrible wounds of war, success may hinge on the first blood clot - the one that begins forming on the battlefield right after an injury. Researchers exploring the complex stream of cellular signals produced by the body in response to a traumatic injury believe the initial response - formation of a blood clot - may control subsequent healing.

18 Feb 2013

Antibody News and Research

Further Reading

EpiCept fourth quarter revenue decreases to $0.1 million

Study designs and tests 60 compounds for their ability to kill human cancer cells

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

XBiotech to enter biosimilar business

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Genetic variation in CD33 influences how AML patients' leukemic cell responds to GO

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

C-section babies more likely to develop allergies

Okairos to commence novel RSV vaccine Phase I clinical trial

Race and possibly genetics play a role in children's sensitivity to developing allergies

Blaze Bioscience completes $8.5 million Series A financing

Antibody delivery system launched that works even in presence of additives

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Possible alternative to biopsy discovered for renal cancer diagnosis

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Antibody test ‘inappropriate’ without connective tissue symptoms

Researchers explore cellular signals produced by the body in response to traumatic injury

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News